Pfizer
Maggie Liu is a Senior Director of Portfolio and Regulatory Strategy at Pfizer, a position held since December 2017, where leadership is provided to a team of nonclinical safety regulatory scientists responsible for the preparation and quality of various regulatory submissions across multiple therapeutic areas. Prior to Pfizer, Maggie Liu served as Director of Science Regulation and Policy at Drinker Biddle & Reath LLP from January 2010 to November 2017, focusing on strategic management and scientific research for industry consortia addressing drug safety and regulatory topics. Earlier experience includes a Postdoc Fellowship in Neuroscience at Johns Hopkins School of Medicine, where research involved identifying genetic regulators of the Semaphorin-Neuropilin signaling pathway. Academic credentials include a PhD in Immunobiology from Yale University and a BS in Biology from Peking University.
This person is not in any teams
This person is not in any offices
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.